← Back to all trials
Not Yet Recruiting
NCT05620784
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
Conditions: BPH With Urinary Obstruction, BPH, Hematuria, Same Day Discharge
Sex: Male
Ages: 18 Years – 89 Years
Healthy volunteers: 1
Phase: PHASE3
Enrollment: 138
Sponsor: Northwestern University
Summary
Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for benign prostatic hypertrophy (BPH) as recommended by the American Urological Association (AUA) Guidelines.
Loop diuretics (furosemide) have been given historically during the morcellation portion of HoLEP to promote urine production in the post-operative setting and to minimize the impact of fluid absorption during long periods of morcellation.
The intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated with the dissemination of HoLEP across North America without evidence to support its routine administration.
With increasing surgical efficiency from improvements in laser and morcellator technology, the role of intra-operative furosemide is unknown.
This study is designed to assess if there is a significant difference in same day discharge rates after Holmium Laser Enucleation of the Prostate (HoLEP) with and without IV furosemide. .
Eligibility Criteria
Inclusion Criteria:Males 18 -89 undergoing HoLEPWilling to sign the Informed Consent FormAble to read, understand, and complete patient questionnaires.Exclusion Criteria:Allergy or hypersensitivity to furosemide or other loop diureticAnuric patients or patients with liver failurePatients having a concurrent ureteroscopy +/- laser lithotripsy, percutaneous nephrolithotomy, or non-urologic surgery at the time of their HoLEPAnticipated need for perineal urethrostomy at the time of HoLEPPatient not undergoing catheter removal and voiding trial at Northwestern Memorial Hospital
Source: ClinicalTrials.gov (NCT05620784). StuddyBuddy aggregates publicly available trial information.